Latest topics page 23
Topics ordered by most recent activity across all 71 subcategories.
1,535 topics · page 23 of 52
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: The topic list is dense — is that deliberate?
Second pass at: The topic list is dense — is that deliberate? I have a specific reason for asking rather than idle curiosity, and the context is below. Nominating something for promotion into the…
|
+102 | 108 | 8.4k | 4mo |
|
[2026 update] Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+40 | 45 | 14k | 4mo |
|
Follow-up: Levothyroxine timing: a real interaction with a simple fix
On the subject in the title: Levothyroxine timing: a real interaction with a simple fix Working notes rather than a conclusion. Reporting something rather than asking about it, in case the pattern is useful…
|
+2 | 6 | 8.1k | 4mo |
|
Rewriting my first post: a before-and-after, with commentary
Rewriting my first post: a before-and-after, with commentary Writing it up because I had to work it out twice and would rather nobody else did. I want to check my reasoning rather than get a conclusion. My…
|
3 | 2.7k | 4mo | |
|
Cost per delivered dose, which is the number that matters
Cost per delivered dose, which is the number that matters — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what…
|
+54 | 59 | 30k | 4mo |
|
Adsorptive losses at low concentration, and why dilute solutions are fragile
Adsorptive losses at low concentration, and why dilute solutions are fragile — setting out what I have, and where I think it stops being reliable. A question about technique rather than about dose. I have…
|
+16 | 20 | 1.7k | 4mo |
|
IGF-1 as a surrogate endpoint and its limitations
IGF-1 as a surrogate endpoint and its limitations Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I do not…
|
+5 | 9 | 35k | 4mo |
|
[2026 update] Distinguishing expected GI effects from something that needs urgent attention
On the subject in the title: Distinguishing expected GI effects from something that needs urgent attention Working notes rather than a conclusion. Reporting something rather than asking about it, in case the…
|
+10 | 14 | 11k | 4mo |
|
Reading an interaction checker output critically
On the subject in the title: Reading an interaction checker output critically Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking rather than…
|
+144 | 152 | 3k | 4mo |
|
Dizziness on standing and the electrolyte explanation
On the subject in the title: Dizziness on standing and the electrolyte explanation Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking rather…
|
+3 | 7 | 147 | 4mo |
|
Which fields on a certificate actually matter, ranked
Which fields on a certificate actually matter, ranked — that is the question, and I have not found it answered plainly anywhere I have looked. Posting the method first, because I know what the first three…
|
+25 | 29 | 46k | 4mo |
|
Why semaglutide solutions can look faintly opalescent and when that matters
The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med ,…
|
+73 | 79 | 2k | 4mo |
|
Nausea profile of amylin analogues compared with GLP-1 agonists
Nausea profile of amylin analogues compared with GLP-1 agonists Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please read it…
|
+70 | 76 | 3k | 4mo |
|
Warfarin and altered intake: the monitoring argument
Warfarin and altered intake: the monitoring argument — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I am asking rather…
|
2 | 11k | 4mo | |
|
A staff appointment, and what the role involves
On the subject in the title: A staff appointment, and what the role involves Working notes rather than a conclusion. Nominating something for promotion into the documentation commons. The topic in question…
|
2 | 1.8k | 4mo | |
|
Introducing myself: pharmacist, sceptic, reluctant participant — one year on
Posting this under the heading it deserves: Introducing myself: pharmacist, sceptic, reluctant participant — one year on Everything below is what sits behind that. Lower-stakes topic, but the sourcing rule…
|
+101 | 107 | 14k | 4mo |
|
Warfarin and altered intake: the monitoring argument — the long version
Posting this under the heading it deserves: Warfarin and altered intake: the monitoring argument — the long version Everything below is what sits behind that. Reporting something rather than asking about it,…
|
+123 | 134 | 40k | 4mo |
|
Second pass at: Circumference measurements as a poor man's composition estimate
Second pass at: Circumference measurements as a poor man's composition estimate — setting out what I have, and where I think it stops being reliable. Longitudinal report with the method stated, because a…
|
+64 | 68 | 13k | 4mo |
|
Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with STEP 4 ( JAMA , 2021) and…
|
+128 | 145 | 3k | 4mo |
|
Oral versus injected administration claims for BPC-157
Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think…
|
+20 | 24 | 47k | 4mo |
|
Revisiting: Maintainer handover: how it works
Revisiting: Maintainer handover: how it works Writing it up because I had to work it out twice and would rather nobody else did. Process question about how this site works. I have read the guidelines and the…
|
+53 | 57 | 664 | 4mo |
|
Revisiting: Reading order for a first week here, and what to skip until later
Posting this under the heading it deserves: Revisiting: Reading order for a first week here, and what to skip until later Everything below is what sits behind that. I want to check my reasoning rather than…
|
2 | 60k | 4mo | |
|
Angle of injection and whether 90 degrees is always right
On the subject in the title: Angle of injection and whether 90 degrees is always right Working notes rather than a conclusion. Reporting something rather than asking about it, in case the pattern is useful to…
|
+105 | 116 | 5.4k | 4mo |
|
Whether protein timing matters at a large deficit
Posting this under the heading it deserves: Whether protein timing matters at a large deficit Everything below is what sits behind that. Longitudinal report with the method stated, because a number without a…
|
+29 | 33 | 7.7k | 4mo |
|
Reconciling a label claim with a content assay
On the subject in the title: Reconciling a label claim with a content assay Working notes rather than a conclusion. I would like to understand what this number means before I repeat it anywhere. A…
|
+2 | 6 | 183 | 4mo |
|
Second pass at: What to keep a record of at the point of payment
Second pass at: What to keep a record of at the point of payment — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually better than…
|
+14 | 18 | 1.9k | 4mo |
|
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016)…
|
+64 | 69 | 27k | 4mo |
|
Realistic expectations for strength while losing weight quickly
Posting this under the heading it deserves: Realistic expectations for strength while losing weight quickly Everything below is what sits behind that. Maintenance rather than loss, which is the part of this…
|
+60 | 70 | 38k | 4mo |
|
Splitting a weekly dose in two: the pharmacokinetic argument against
Splitting a weekly dose in two: the pharmacokinetic argument against — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I…
|
+24 | 28 | 51k | 5mo |
|
How the published trials escalated, tabulated side by side
The question in the title: How the published trials escalated, tabulated side by side I will give what I have already checked below so nobody repeats it. A question about technique rather than about dose. I…
|
+4 | 8 | 4.2k | 5mo |